REPRIEVE Study
Protecting One's Heart
The REPRIEVE study aims to prevent cardiovascular disease
by Chael Needle
As people are living longer with HIV, researchers have been increasingly attending to...
PRO 140
Chronic Relief?
A self-injectable monoclonal antibody vies to become a monotherapy
by Chael Needle
Anti-HIV agents currently being researched these days seem split between (1) improving regimens...
Revisiting Immunity
NAPWA helps to promote immune-based therapies
by Chael Needle
At the International AIDS Conference last June, the AIDS Institute and the National Association of People with AIDS...
FDA Approves First Two-Drug Once-Daily Single-Pill HIV Regimen
On November 21, 2017, the U.S. Food and Drug Administration (FDA) approved the first-ever two-drug once-daily single-pill regimen for the maintenance treatment of adults...
SMYD2 & the HIV Reservoir
Shock Value
Research on SMYD2 shows potential to wake up the HIV reservoir
by Chael Needle
HIV latency—where HIV hides out in reservoirs, dormant and beyond the...
Targeting Dual Points of Entry
LifeGuide
Two Birds, One Stone
Researchers make advances with agents that can target dual points of entry
by Mariel Selbovitz, MPH
Drug discovery and early to mid-stage drug...
HIV Therapeutic Vaccine Advances
Treatment Horizons
Another Kind of Morning
HIV therapeutic vaccines try to come of age
by Mariel Selbovitz, MPJ, and David Miller
Despite over three decades of research on...
Silk-Protein Film
LifeGuide
Blocking the First Step
A silk-protein film aims to become an HIV prevention method
by Chael Needle
When we think of HIV prevention in sexually active...
Under One Roof: ViiV Healthcare Strives for New HIV Treatments
If we think of HIV as carrying a kind of a malware that takes over human T cells and turns them into a machine...
Man Up Mondays
An independent interim review of the Strategic Timing of AntiRetroviral Treatment (START) study findings shows that initializing treatment early improves outcomes for individuals with...
LATEST POSTS
Vaccine in Imbokodo Study Fails to Provide Protection
Phase 2b HIV Trial Vaccine Fails
Preliminary analysis of the Imbokodo study of an experimental HIV vaccine demonstrated that the vaccine did not provide sufficient...
